Announcement of the financial report
for the year of 2021
Date of events
2022/03/09
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/03/09
2.Date of the audit committee approved:2022/03/09
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2021/01/01~2021/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):4,535,610
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):2,766,553
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):1,140,652
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):1,087,380
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):822,569
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):831,894
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):3.35
11.Total assets end of the period (thousand NTD):9,296,465
12.Total liabilities end of the period
(thousand NTD):3,529,231
13.Equity attributable to owners of parent end of the
period (thousand NTD):5,167,855
14.Any other matters that need to be specified:None.
Attachments
Original Link
Original Document
Permalink
Disclaimer
TTY Biopharm Co. Ltd. published this content on 09 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 March 2022 13:21:09 UTC.
TTY Biopharm Co Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of pharmaceutical preparations. The Company mainly operates through six business segments including Cancer Drug segment, Healthcare segment, Anti-Infective Drug segment, Domestic Cardiovascular and Gastrointestinal Drug segment, Mainland Medical Drug segment and the Other segment. The main products include oncology medicines, anti-infective medicines and health care medicines. Oncology medicines are mainly anti-cancer and auxiliary drugs. Anti-infective medicines are mainly back-line antimicrobial agents and influenza vaccines. Medical and health care medicines are mainly gastrointestinal health care, bone health care, metabolic health care, infection treatment drugs. The Company distributes its products in domestic and overseas markets.